LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

Strona główna・Stock List・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Closed

4.03 2.28

Buy Sell

Overview

Share price change

24h

Current

Min

3.93

Max

4.03

Key metrics
By Trading Economics
Income	5.5M -28M
Sales	8.2M 13M
EPS	-0.47
Profit margin	-208.694
Employees	172
EBITDA	8.7M -27M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+236.72% upside

Market Stats
By TradingEconomics
Market Cap	-27M 228M
Previous open	1.75
Previous close	4.03

Technical Score

By Trading Central

Confidence

Bearish Evidence

3.17 / 3.4644 Support & Resistance

Voyager Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

27 lis 2025, 16:49 UTC

Acquisitions, Mergers, Takeovers

Deutsche Boerse in Talks to Buy Fund-Tech Platform Allfunds in $6 Billion Deal

27 lis 2025, 15:32 UTC

Acquisitions, Mergers, Takeovers

TotalEnergies, Repsol in Talks to Combine U.K. North Sea Assets, Cinco Dias Says, Citing Sources

27 lis 2025, 23:50 UTC

Market Talk

Nikkei May Trade Rangebound Amid Caution Over Economic Outlook -- Market Talk

27 lis 2025, 23:50 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27 lis 2025, 16:05 UTC

Market Talk

Canadian Job Vacancies Rise for Fist Time Since Start of 2024 -- Market Talk

27 lis 2025, 16:04 UTC

Market Talk

Canadian Payroll Employment Pulls Back in September, Offsetting Recent Gains -- Market Talk

27 lis 2025, 15:54 UTC

Acquisitions, Mergers, Takeovers

Allfunds Shares Rise 21% After Deutsche Boerse Says Started Acquisition Talks

27 lis 2025, 15:44 UTC

Acquisitions, Mergers, Takeovers

Deutsche Boerse: No Certainty Talks Will Result in Transaction

27 lis 2025, 15:43 UTC

Acquisitions, Mergers, Takeovers

Deutsche Boerse: Allfunds Board of Directors Has Agreed to Enter Exclusive Talks

27 lis 2025, 15:42 UTC

Acquisitions, Mergers, Takeovers

Deutsche Boerse: Nonbinding Proposal is To Acquire Allfunds at EUR8.80 a Share

27 lis 2025, 15:41 UTC

Acquisitions, Mergers, Takeovers

Deutsche Boerse in Talks With Allfunds on Possible Acquisition

27 lis 2025, 15:11 UTC

Market Talk

Dollar Could Fall in 2026 as U.S. Rate Cuts Bite -- Market Talk

27 lis 2025, 14:26 UTC

Market Talk

Hermes' Outperformance Gap Could Narrow -- Market Talk

27 lis 2025, 14:11 UTC

Market Talk

Lack of Major Budget Surprises Don't Justify Continued Sterling Strength -- Market Talk

27 lis 2025, 14:11 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

27 lis 2025, 13:35 UTC

Market Talk

Richemont Looks Set to Continue Outgrowing Peers -- Market Talk

27 lis 2025, 13:33 UTC

Market Talk

Sterling's Post-Budget Gains Are Probably Over -- Market Talk

27 lis 2025, 13:22 UTC

Market Talk

Global Equities Roundup: Market Talk

27 lis 2025, 13:22 UTC

Market Talk

Kering's Plan to Revive Gucci Needs More Clarity -- Market Talk

27 lis 2025, 13:17 UTC

Market Talk

LVMH Should Be Able to Recover Next Year -- Market Talk

27 lis 2025, 11:13 UTC

Market Talk

European Gas Prices Come Under Pressure -- Market Talk

27 lis 2025, 11:07 UTC

Earnings

Genting: Positive About Prospects Over Longer Term

27 lis 2025, 11:06 UTC

Earnings

Genting: Cautious on Near-Term Prospects of Leisure, Hospitality Industry

27 lis 2025, 11:04 UTC

Earnings

Genting: International Travel Demand Expected to Remain Resilient

27 lis 2025, 11:04 UTC

Earnings

Genting: Global Growth Expected to Remain Subdued

27 lis 2025, 11:04 UTC

Earnings

Genting: Ebitda Partly Weighed by Stronger Ringgit Vs. Singapore Dollar, British Pound, U.S. Dollar

27 lis 2025, 10:59 UTC

Earnings

Genting Bhd 3Q Net Profit Fell 86% on Year

27 lis 2025, 10:58 UTC

Earnings

Genting Bhd 3Q Rev Rose 14% on Year

27 lis 2025, 10:56 UTC

Earnings

Genting Bhd 3Q Net MYR30.3M

27 lis 2025, 10:56 UTC

Earnings

Genting Bhd 3Q EPS MYR0.0079

Peer Comparison

Price change

Voyager Therapeutics Inc Forecast

Price Target

By TipRanks

236.72% upside

12 Months Forecast

Average 13.57 USD 236.72%

High 25 USD

Low 8 USD

Based on 9 Wall Street analysts offering 12 month price targets forVoyager Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

9 ratings

Buy

Hold

Sell

Based on 9 analysts giving stock ratings to Voyager Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

3.17 / 3.4644Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.